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Abstract  
Purpose: A low mutation rate seems a general feature of pediatric cancers, in par-
ticular in oncofusion gene driven tumors. Genetically, Ewing sarcoma (ES) is defined 
by balanced chromosomal EWS/ETS translocations, which give rise to oncogenic 
chimeric proteins (EWS-ETS). Other contributing somatic mutations involved in dis-
ease development have only been observed at low frequency.  
Experimental design: Tumor samples of 116 Ewing sarcoma (ES) patients were 
analyzed here. Whole Genome Sequencing was performed on two patients with 
normal, primary and relapsed tissue. Whole Exome Sequencing was performed on 
50 ES and 22 matched normal tissues. A discovery data set of 14 of these tu-
mor/normal pairs identified 232 somatic mutations. Recurrent non-synonymous muta-
tions were validated in the 36 remaining exomes. Transcriptome analysis was per-
formed in a subset of 14/50 ES and DNA copy number gain and expression of 
FGFR1 in 63/116 ES.  
Results: Relapsed tumors consistently showed a 2- to 3-fold increased number of 
mutations. We identified several recurrently mutated genes at low frequency 
(ANKRD30A, CCDC19, KIAA0319, KIAA1522, LAMB4, SLFN11, STAG2, TP53, 
UNC80, ZNF98). An oncogenic fibroblast growth factor receptor 1 (FGFR1) mutation 
(N546K) was detected, and the FGFR1 locus frequently showed copy number gain 
(31.7%) in primary tumors. Furthermore, high-level FGFR1 expression was noted as 
a characteristic feature of ES. RNA-Interference of FGFR1 expression in ES lines 
blocked proliferation and completely suppressed xenograft tumor growth. FGFR1 TKI 
inhibitor therapy in a patient with ES relapse significantly reduced 18-FDG-PET activ-
ity. 
Conclusions: FGFR1 may constitute a promising target for novel therapeutic ap-
proaches in ES.  
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Translational relevance: Pediatric cancers including Ewing sarcoma are character-
ized by a low mutation count with difficult to target driver lesions. Our investigation 
provides evidence that integration of sequencing data with gene amplification, ex-
pression and functional analysis are crucial to identify oncogenic drivers in cancers 
with low rates of recurrent mutations. By this approach aberrant FGFR1 activity 
emerged as a novel target for Ewing sarcoma. FGFR1 inhibitors are in clinical trials 
for other cancers and could be tested in Ewing sarcoma with different ways of 
FGFR1 activation.  
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Introduction 
Ewing sarcoma (ES) is a highly malignant bone and soft tissue neoplasia of still en-
igmatic histogenesis with a prominent stemness phenotype (1, 2). Histogenesis may 
be endothelial, neuroectodermal (3-5) or osteochondrogenic (6, 7) Genetically, ES is 
defined by specific balanced chromosomal EWS/ETS translocations which give rise 
to oncogenic chimeric proteins (EWS-ETS), the most common being EWS-FLI1 as a 
consequence of the t(11;22)(q24;q12) translocation (8-11).  
EWS-ETS chimeric proteins promote cell transformation through abnormal regulation 
of specific target genes involved in the control of a variety of cellular processes (12). 
However, little is known about cooperating events that affect oncogenesis and/or 
progression of ES. TP53 mutations and CDKN2A deletions are known to confer poor 
prognosis but are infrequently observed for this sarcoma (approx. 13 % of cases) 
(13). Furthermore, despite a relatively stable genome, copy number alterations 
(CNA) are recurrently observed in ES (14), but only 1q gains as detected in 31 % of 
tumor samples seem to be associated with poor prognosis (15). In genome-wide as-
sociation studies (GWAS), few genomic loci were associated with susceptibility (16).  
Cancer arises due to genetic mutations that alter the function of a wide array of 
genes (17). Cancer genomes are often aneuploid, contain amplifications and dele-
tions, and typically comprise hundreds to thousands of DNA point mutations. Howev-
er, not all cancers are necessarily that complex. Large-scale sequencing projects 
have revealed that mutation rates display 10- to 100-fold differences among cancer 
types and even among different cancers of the same type (18-20). A low mutation 
rate appears to be a general feature of pediatric cancers (21), challenging the view 
that genomic instability is critical for tumor progression. A low mutation frequency so 
far has been observed in medulloblastoma (22), rhabdoid cancers (23), glioblastoma 
(24), retinoblastoma (25), and seems to be a feature of ES (20). Hence, the patho-
mechanisms of ES and suitable molecular therapeutic targets have mostly remained 
elusive. However, even in translocation-driven tumors, multiple clones with varying 
genetic aberrations and driving capacity for the disease may occur (26). ES has been 
reported to contain a low number of mutations in coding regions (20). Given the still 
dismal prognosis of advanced ES (27, 28), we performed whole genome sequencing 
of diagnosis and relapse samples to identify potential drivers and relapse associated 
genes. Further, we performed exome sequencing to expand the findings and to iden-
tify novel therapeutic targets.   
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Materials and Methods 
Patient material  
Patient material was obtained from clinical studies of the Cooperative Ewing Sar-
coma Study Group (CESS) in Europe. All patients provided informed consent. 
Nucleic acid extraction  
We extracted nucleic acids from peripheral blood leukocytes, tumor material and cell 
cultures by use of either the DNAeasy or the RNAeasy Blood and Tissue Kit (Qiagen, 
Hilden, Germany) according to the suppliers recommendations.  
Whole genome sequencing (WGS) 
WGS was performed at Complete Genomics using 10 µg of high molecular weight 
DNA. Sequences were mapped to the National Center for Biotechnology Information 
(NCBI) reference genome build 37. Unless explicitly stated otherwise, all computa-
tions were performed using the statistical environment R (http://www.r-project.org).  
Exome sequencing 
Exomes were enriched in solution with SureSelect XT Human All Exon 50 Mb kits 
(Agilent Technologies, Santa Clara, CA, USA) and sequenced as 100 bp paired-end 
runs using TruSeq SBS chemistry v3 (Illumina, San Diego, CA, USA) generating 5-
12 Gb of sequence and an average read depth between 66 and 166 on target re-
gions. More than 90 % of the target regions were covered 20 times or more. Bur-
rows-Wheeler Aligner (BWA v 0.5.9) with standard parameters was used for read 
alignment against the human genome assembly hg19 (GRCh37). We performed sin-
gle-nucleotide variant and small insertion and deletion (indel) calling for the regions 
targeted by the exome enrichment kit using SAMtools (v 0.1.18). Large indels were 
called with Pindel (v 0.2.4t) and copy number variations (CNV) were determined us-
ing the R package ExomeDepth (v 0.9.7). 
To discover putative somatic variants, we retrieved only those variants of a tumor 
that were not found in the corresponding control tissue. To reduce the number of 
false positives, we filtered out variants that were already present in 3,600 “in house” 
control exomes (patients with unrelated diseases and healthy controls from other 
projects) or had variant quality of less than 30. Furthermore, the variants were filtered 
according to several quality criteria using the SAMtools varFilter script. We used 
default parameters, with the exception of the maximum read depth (-D) and the 
minimum P-value for base quality bias (-2), which we set to 9999 and 1e-400, 
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respectively. Moreover, we applied a custom script that marked all variants where the 
median base quality of adjacent bases was low, because these variants are often 
sequencing artifacts. We then manually investigated the raw read data of the 
remaining variants using the Integrative Genomics Viewer (IGV v2.3.19). 
 
FGFR1 copy number 
Real time PCR. FGFR1 gene copy number was determined using TaqMan copy 
number assays (Life Technologies) according to the supplier’s protocol. In brief each 
10 ng of genomic DNA were used for duplexed real time PCRs targeting human 
FGFR1 and RNase P gene. Reactions were carried out in duplicates. Gene copy 
number was calculated using Copy Caller v2.0 software. 
Interphase fluorescent in situ hybridization (FISH). Cells were grown under 
standard culture conditions. Standard cytogenetic techniques were used for harvest-
ing, isolation of interphase nuclei and slide preparation. FISH was carried out using a 
dual labeled break apart probe (Kreatech) targeting FGFR1 and surrounding se-
quences of 1.1 MB length and a centromere 8 probe. Nuclei were counterstained 
with DAPI. 
FGFR1 expression  
Immunohistochemistry. Slides of the 41 Ewing sarcoma samples were deparaf-
finized and rehydrated. Primary antibody targeting FGFR1 and HRP coupled sec-
ondary antibody was used for antigen detection. Staining intensities were graded 
semi-quantitatively based on the percentage of positive cells(0: negative, 1: <25%, 2: 
<50%, 3: >50%) using positive controls recommended by the antibody supplier. 
Real-Time RT PCR. Reverse transcribed mRNA of 61 ES was used for quantification 
of FGFR1 expression by means of SYBR green real-time PCR. GAPDH was used as 
housekeeping gene and FGFR1 expression was calculated relative to the expression 
in the ES cell line VH-64 using the 2^-delta CT method. 
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In vitro studies 
FGFR1 knock-down and proliferation. Cells were lentivirally transduced with the 
vector pLKO-GFP containing 2 different shRNAs against human FGFR1. Scrambled 
shRNA sequence cloned into pLKO-GFP served as control. Cells were FACS sorted 
for GFP expression after 48 hours. For adherent cell lines (A673, SK-NMC, A549) 
50,000 cells per well were seeded into 24 wells in a 12-well plate format whereas 
5,000 cells were used for suspension cell lines (KASUMI, HL60). Cells were cultured 
under standard conditions in RPMI-Medium containing 10 % FCS. Cell numbers 
were determined every day for 5 consecutive days. Biological replicates were per-
formed. 
FGFR1 mutagenesis and proliferation. FGFR1 cDNA (ThermoFisher CloneID: 
3911101) was mutated (N546K) using the QuikChange Lightning Site-Directed Mu-
tagenesis Kit (Agilent Technology) following the suppliers instructions. Wildtype and 
mutated cDNA was cloned into MSCV2.2- GFP and transduced into NIH-3T3 cells 
using standard techniques. Effect of N546K on proliferation was analyzed as de-
scribed above for adherent cell lines. 
FGFR1 mutagenesis and colony forming. Soft agar assays were used to deter-
mine the effect of N546K on colony forming capacity. Briefly, 10,000 cells per well 
were transduced with either control, wildtype or mutated FGFR1. After mixing with 
agarose and plating they were allowed to form colonies for 7 days. 
Animal model 
Immune deficient Rag2-/-γC-/- mice on a BALB/c background were obtained from the 
Central Institute for Experimental Animals (Kawasaki, Japan) and maintained in our 
animal facility in Munich under pathogen-free conditions in accordance with the insti-
tutional guidelines and approval by local authorities. Experiments were performed in 
5 mice/group at the age of 6-10 weeks. 
In vivo experiments 
For the analysis of in vivo tumor growth cells were harvested by trypsinization, 
washed with Dulbecco's phosphate buffered saline, and injected in a volume of 0.2 
ml into immune deficient Rag2-/-γC-/- mice. To investigate local tumor growth, 2 x 106 
ES cells and derivatives were injected subcutaneously into the groin using a 26-
gauge needle attached to a 1 ml syringe. Tumor size was determined as described 
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(1). Mice bearing a tumor > 10 mm in diameter were considered as positive and sac-
rificed.  
Additional statistical analysis  
Descriptive statistics is used to determine parameters like mean, standard deviation 
and standard error of the mean (SEM) from more than two independent experiments. 
Differences were analyzed by unpaired two-tailed student’s t-test as indicated using 
Excel (Microsoft) or Prism 5 (GraphPad Software); p values < 0.05 were considered 
statistically significant (*p < 0.05; **p < 0.005; ***p < 0.0005). 
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Results 
Specimens from 116 Ewing sarcoma (ES) patients were investigated in this project. 
Matched normal, primary and relapse specimens from two patients were analyzed by 
whole genome sequencing (Fig.1; green labeled probes). For exome sequencing and 
expression analysis we utilized tumor samples of 51 patients (Fig.1; ES001-ES051). 
For 24 of these patients normal tissue controls were available. We performed whole 
exome sequencing (WES) in a discovery set of 14 of the matched tumor/normal 
sample pairs that was selected based on average coverage and high tumor content 
(for 7 primary only, for 6 relapsed only and for one both, (Fig.1, orange labeled 
probes). As a validation cohort we performed exome sequencing on further 36 ES 
patients (17 primary with three matched normal tissues, 18 relapses with five 
matched normal tissues and one with primary and relapse) for the detection of recur-
rent mutations. Expression data were obtained from tumor material from 14/53 pa-
tients, which were analyzed by WES and compared to a normal body map of 21 dif-
ferent healthy tissues (NBA, see Supplementary Materials and Methods). Finally, the 
remaining 63/116 ES patient samples were utilized for analysis of FGFR1 DNA copy 
number gain, mRNA profiling and immunohistochemistry. Combined patient charac-
teristics and subjected methods are shown in Fig. 1 and Supplementary Fig. S1. 
Whole genome sequencing (WGS) in patients with relapses of Ewing sarcoma 
(ES). Patient #1 was a 36-year old male with first diagnosis of ES in the left tibia. One 
year after multimodal therapy the patient relapsed locally. A second local relapse oc-
curred along with lung metastases one year later. Ultimately, the patient died of the 
disease 8 months later. WGS was performed using specimens obtained from the first 
and second relapse and peripheral blood as germline control. 
The female patient #2 was 12 years old at diagnosis of the primary tumor in the left 
pubic bone and the left acetabulum and lung metastases. She was treated according 
to the EURO-Ewing-99-protocol. The first relapse, lung metastases and local recur-
rence, occurred 2 years after diagnosis. Three years later the second pulmonary re-
lapse was diagnosed. Samples for WGS were taken from peripheral blood, the pri-
mary tumor and two consecutive pulmonary relapses.  
In both patients, the EWS-FLI1 mutation was present in all diagnostic and relapse 
samples. 
Randomly selected somatic mutations obtained via whole genome sequencing were 
verified by Sanger sequencing to develop receiver-operating curves (ROC) that ena-
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bled accurate quantitation of mutation load per mega base (Supplementary Table S1 
and Fig. S2). In the female patient, the total number of somatic mutations was 1325 
and doubled with each relapse (1st relapse = 3229 mutations; 2nd relapse = 6443 mu-
tations), indicating that recurrent disease appeared to consistently double the number 
of somatic mutations (Fig. 2A). Similar findings were obtained in the male patient with 
2506 mutations at first sample and 6219 mutations in the second sample. Interesting-
ly, the 2- to 3-fold increase in mutation rate for each relapse was consistent among 
different types of mutations. For single nucleotide variations there was a 1.9- to 2.5-
fold increase in mutation frequency. Deletions occurred in relapsed samples at a 2.7- 
to 3.2-fold increase compared to the previous specimen (Supplementary Fig. S2B). 
These findings suggest, that despite different treatments, the increasing genomic 
instability of ES is evenly distributed among different mutation types. Nonetheless, 
deletions occurred up to two times more frequently than insertions. This trend was 
observed in all direct comparisons of recurrence with previous tumor stage. Between 
100 and 500 mutations per specimen affected exonic regions. Of these, only a minor-
ity between 27 and 115 were found as tier 1 mutations with expected functional con-
sequences for coding proteins (Fig. 2B). In line, a strong increase was observed from 
the time of diagnosis to the consecutive relapsed situations (patient #1: 1st relapse = 
61 mutations; 2nd relapse = 109 mutations; patient #2: primary = 27 mutations; 1st 
relapse =  62 mutations;  2nd relapse = 115 mutations). The increase in mutation fre-
quency was about 2-fold (Supplementary Fig. S2C). Mutations were evenly distribut-
ed throughout the genome in the male patient (Supplementary Fig. S3A left) as well 
as in the female patient with primary tumor, first and second relapse (Supplementary 
Fig. S3A right). A further analysis of the mutation types for single nucleotide varia-
tions revealed, that Cytosine conversions into Thymidine were most frequent fol-
lowed by Adenosine (A) to Guanosine (G) transversions (Fig. 2C) which was similarly 
observed after exome sequencing (Fig. 3D). C to T conversions are frequently ob-
served in damaged long single-strand DNA-regions due to the activity of APOBEC 
enzymes (29, 30). Of note, in the second relapse of the female patient the A to G 
mutation was most frequently observed. 
In the female patient, two major clones were observed at the time of diagnosis (Fig. 
2D). At the time of first relapse and second relapse only one predominant clone was 
observed with indications for smaller subclones. In the male patient only one major 
clone was observed and one predominant clone was present also at the time of sec-
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ond relapse. These findings indicate that clonal heterogeneity does exist in ES. Also, 
similar to other cancers it is likely, that clonal selections occur via chemotherapy and 
are associated with fewer subclones in relapses.  
Whole exome sequencing of ES patient samples. In addition to whole genome 
sequencing in primary and relapse patients we sought to further identify the spectrum 
of mutations in ES. In a discovery data set of 14 individual patients (7 primary, 6 re-
lapsed and one patient where both, primary and relapse were available) we analyzed 
matched tumor/normal pairs. High tumor cell content, the availability of matched 
normal tissue and the high quality and amount of DNA enabled exome sequencing 
analysis with especially high sensitivity and specificity. As a validation cohort we per-
formed exome sequencing of further 36 ES (17 primary, 18 relapses and one with 
both) for the detection of recurrent mutations; part of them (8 samples) matched to 
normal controls. The ES samples in the discovery cohort in their majority exhibited 
EWS/FLI1 translocations (Supplementary Table S2). To reduce the number of false 
positives, we filtered out variants that were already present in 3,600 “in house” 
control exomes (see Materials and Methods). The matched tumor/normal pairs were 
used to identify the rate of somatic mutations per megabase exomes. We identified 
232 somatic mutations in 14 ES, of which 166 were damaging mutations leading to 
loss of protein function. On average 0.38 somatic mutations per megabase were ob-
served in ES. Most of these mutations were non-synonymous mutations (Fig. 3A). 
Pediatric tumors have been reported to harbor a low number of mutations (21), a 
finding that was recapitulated in our study. However, ES also occurs in adult patients. 
Importantly, in our investigation the mutation rate did not increase significantly with 
age of the patient (Fig. 3B). This indicates that age is not the determining factor for 
the number of mutations in ES. Also, higher mutation load and increased genomic 
instability might not be the reason for the less favorable outcome of ES in adult pa-
tients. Primary tumors harbored on average 9 mutations per exome whereas around 
18 mutations per exome were found in relapsed tumors (Fig. 3C). This again is in line 
with the finding in the whole genome sequencing that relapses are associated with a 
2- to 3-fold increased number of somatic mutations. Examples comprising mutation 
patterns in particular patients are given in Supplementary Fig. S3B. 
For subsequent analysis of mutation frequency, 36 additional ES samples were in-
vestigated by whole exome sequencing. This approach identified a set of recurrently 
mutated genes. The further examination was performed according to presumed vari-
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ations in patient-specific mutation frequency and gene-specific background mutations 
by use of the MutSig algorithm (http://www.broadinstitute.org/cancer/cga/mutsig). 
The MutSig analysis led to a list of genes with non-synonymous mutation frequencies 
ranging from 5.7 % to 11.5 % (Table 1, Supplementary Table S4). Mutations in e.g. 
ankyrin repeat domain-containing protein 30A (ANKRD30A; at 9.6 %), coiled-coil 
domain containing protein 19 (CCDC19, at 11.5 %), laminin, beta 4 (LAMB4; at 9.6 
%), schlafen family member 11 (SLFN11; at 7.7 %), unc-80 homolog (UNC80; at 7.7 
%), and zinc finger protein 98 (ZNF98; at 7.7 %) may involve different aspects of tu-
mor pathology presumably important but not essential for disease development.  
However, such recurrent mutation as filtered by the MutSig algorithm where of low 
statistical significance (with no FDR value below 0.1; table 1). Silencing mutations of 
stromal antigen 2 (STAG2) in ES were recently described (31-34) and were con-
firmed by Sanger sequencing (Supplementary Fig. S4A). The presumed aneuploidy 
in cases with STAG2 mutations as described by others (31) was not confirmed in our 
study similar to other published observations (35).   
Comparison with expression data interestingly demonstrated an up-regulation of 
SLFN11 (fold change (FC) = 10.9), STAG2 (FC = 2.1), and TP53 (FC = 1.79) in ES 
when compared to the mean of a normal body map of healthy tissue (NBA, see Sup-
plementary Materials and Methods) (Table 1, Supplementary Table S4, S5). Others, 
like ANKRD30A, CCDC19, LAMB4, or ZNF98 were ubiquitously expressed while 
some were up in brain or fetal brain tissue such as KIAA0319, KIAA1522, or UNC80, 
which is also true for STAG2. 
Furthermore, analysis of overlapping somatic mutations in three different patient tri-
plets of primary and relapsed tumor samples (Pat.1 and 2, and ES014) revealed re-
current mutations for each patient (Supplementary Table S5). Overall a large amount 
of mutations were shared in consecutive sarcomas (Pat. 1: 61 mutations in relapse 1, 
of these 42 shared with relapse 2; Pat. 2: 27 mutations in primary, of these 8 shared 
with relapse 1 and/or relapse 2; ES014: 13 mutations in primary, of these 9 shared 
with metastasis). 
Overall, the observed low frequency of recurrent non-synonymous mutations of 
which only STAG2 seemed to be statistically significant suggests that collaborative 
events in ES do not require single nucleotide variation in addition to EWS/ETS trans-
locations. 
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Deregulation of FGFR-1 in ES. Exome sequencing was performed to identify novel 
driver genes in Ewing sarcoma. Interestingly, one somatic mutation in the male pa-
tient with ES that underwent WGS was a known oncogenic mutation in FGFR1. This 
mutation (N546K) occurred in the tyrosine kinase domain (Fig. 4A) and was inde-
pendently discovered as an activating mutation in pilocytic astrocytoma and glioblas-
toma (36, 37). This mutation was confirmed in all tumor specimens from this patient 
(Supplementary Fig. S4B). Sanger sequencing of the FGFR1 kinase domain in 30 
additional Ewing sarcoma specimens did not reveal additional mutations (data not 
shown). As a complementary approach for the identification of driver events, we uti-
lized exome data to identify copy number variations. Deletions involving different ex-
ons of cyclin-dependent kinase inhibitor 2a (CDKN2A) (15) were observed in 4 of 14 
tumors, but gain of chromosome 8, that was found in 5 of the 14 tumors, was among 
the most frequent alterations (Fig. 3E). This is in line with previous findings (15), (38). 
Trisomy 8 as well as amplifications of chromosome 8 are the most frequent cytoge-
netic findings in ES (14). The relevant gene or the relevant genes have not been 
identified so far. Of note, all amplifications involve the FGFR1 gene.  
FGFR1 is located on chromosome 8p, and we next analyzed the copy number status 
of FGFR1 in ES. A real time PCR-based method identified a gain of the FGFR1 locus 
in 13 of 41 patients (31.7 %). Of these, 12 patients had gained one copy and one 
patient harbored four gene copies (Fig. 4C). Our analyses included copy number 
gains due to chr8 amplification as well as direct gene copy number gain. FGFR1 
copy numbers closely correlated with FGFR1 gene expression (Fig 4D). Gains of 
FGFR1 copy number did not only occur in primary tumors, but were consistently ob-
served in ES cell lines A673, CADO, SK-NMC, SK-ES, and VH-64. Copy number 
gains of FGFR1 occur due to trisomy 8 in the majority of patients but a proportion of 
patients and cell lines also showed amplification beyond three copies of the entire 
chromosome. (Fig. 4B 
In line, FGFR1 was highly expressed in ES on the mRNA level (Supplementary Fig. 
S5A and S5B) and on the protein level as indicated by immunohistochemistry (Fig. 
4E and F).  
Functional analyses of FGFR1 expression in ES. Activating mutations, copy num-
ber gains and other alterations as well as increased expression of FGFR1 occur in 
ES (e.g. compared to normal tissue, Supplementary Fig. 5B) with a high frequency. 
We therefore further analyzed the potential role of FGFR1 in ES. First, we retrovirally 
 14 
transduced FGFR1 wild type or the FGFR1 N546K mutant into NIH3T3 cells. Both, 
overexpressed FGFR1 wild type and the N546K mutation enhanced proliferation 
(Fig. 5A). In colony formation assays, FGFR1 N546K mutation more than quadrupled 
the number of colonies obtained after empty vector transduction, whereas the 
FGFR1 wild type doubled colony formation (Fig. 5B). The transformation of NIH3T3 
cells by FGFR1 wild type and FGFR1 N546K mutation is also indicated in Fig. 5C by 
the formation of three-dimensional clusters. Alterations of FGFR1, especially the gain 
of the locus as well as expression of the protein, were associated with a trend to-
wards inferior survival in patients with ES (Supplementary Fig. S6).  
To analyze whether FGFR1 signaling was required for ES growth, we performed 
shRNA-based knock-down after transduction with lentiviral constructs encoding 
scrambled (pLKO_shcontrol) or FGFR1 specific shRNA (pLKO_shFGFR1), respec-
tively. Specific shRNA knock-down suppressed FGFR1 mRNA expression by 70 % 
or more in ES cell lines and was confirmed on the protein level, too (Supplementary 
Fig. S5C and S5D). Knock-down of FGFR1 inhibited growth of ES and other cancer 
cells such as the A549 lung carcinoma cell line or the leukemia cell lines HL60 and 
Kasumi. Of note, almost complete growth suppression was observed only in the ES 
cell lines (Fig. 5D).  
To analyze whether FGFR1 inhibition was also relevant for ES growth in vivo, lentivi-
rally transduced A673 ES cells were injected into Rag2-/-γC-/- mice (6). Viability at the 
time of injection was 100 % for both scrambled (pLKO_shcontrol) and FGFR1 shRNA 
(pLKO_shFGFR1) transduced cell lines. However, mainly scrambled transduced 
A673 cells formed tumors in mice (100 %), whereas only in one mouse a tumor was 
formed by FGFR1 shRNA (pLKO_shFGFR1) transduced cells. Tumor growth and 
survival curves are shown in Fig. 5F and 5G. These findings suggested that FGFR1 
is a crucial signaling pathway for Ewing sarcoma. 
Ponatinib is a tyrosine kinase inhibitor that among others, effectively targets FGFR1 
at low nanomolar concentrations (39). Accordingly, proliferation of all tested ES cell 
lines was inhibited by Ponatinib treatment in the nanomolar range of concentrations 
(Fig. S6C). One patient with ES, who had exhausted all other treatment options, was 
offered Ponatinib treatment. FGFR1 inhibition by Ponatinib elicited a response by 
significantly decreasing the glucose uptake of the tumor (Supplementary Fig. S6D, 
Supporting information). the treatment effect was not maintained and the patient 
eventually died with clinical progress of CNS metastases (brain and meninges). 
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DISCUSSION 
Pediatric malignancies, and especially ES, have been reported to contain few if any 
recurrent mutations (21, 33, 34). Our study leads to important novel insights into the 
pathogenesis of ES. First, the mutation load in ES remains very low on whole ge-
nome as well as whole exome sequencing level. No frequent genetic driver mutation 
besides the well described EWS/ETS translocation was identified (40). Mutation load 
did not depend on age at diagnosis which suggests that mutation load does not play 
an important factor for the worse prognosis observed in adult patients. It appears that 
the number of observed mutations in ES is disease specific and was not closely as-
sociated with patient age at the time of diagnosis. This is in contrast to age-
associated cancers such as AML, which show increased mutation load in older pa-
tients (41). Despite the unifying events of the balanced EWS/FLI1 translocation, 
clonal subpopulations exist. These contain different mutations, which are only partial-
ly overlapping. Signs of clonal selection are present in relapse specimens and each 
relapse was associated with a 2- to 3-fold increase in somatic mutation load com-
pared to the primary tumor or the previous relapse. So far, no targetable mutations 
had been reported in ES. In our study, we identified alterations of the FGFR1 gene 
as a highly frequent event in ES pathogenesis. We initially discovered a somatic 
point mutation in the tyrosine kinase domain with activating activity in two subsequent 
relapse specimen indicating stability of the mutation. The structural analysis of this 
mutation (37) as well as functional analyses provide evidence that this N546K muta-
tion induces enhanced FGFR1 activity and increased proliferation. In addition, 
wildtype FGFR1 is overexpressed in many ES tumors. Forced expression of FGFR1 
increased proliferation and clonogenic growth in fibroblasts. Intriguingly, copy number 
gain of FGFR1 was detected in a substantial fraction of ES either due to gene ampli-
fication or Trisomy 8 cytogenetic aberration. Trisomy 8 is the most frequent cytoge-
netic aberration that is found in ES but no involvement of a specific gene locus was 
identified so far (14), (38). Accordingly, FGFR1 was highly expressed on the protein 
level in almost all analyzed ES. Gene amplification and overexpression are crucial 
pathogenetic mechanisms for growth factor receptors activation in multiple cancers 
(42, 43). For example, EGFR amplification and overexpression with subsequent au-
to-activation has been described in breast cancer and lung cancer. Along the same 
line, Her2 /NEU/ERBB2 amplification and expression is of pathogenetic relevance in 
breast cancer and associated with a poor prognosis (44). The potential relevance of 
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FGFR1 for ES was suggested in our data by the association of high FGFR1 expres-
sion levels with increased relapse rates and more importantly by the fact, that sup-
pression of FGFR1 abolished the growth of ES cell lines. This phenomenon was evi-
dent for all analyzed ES cell lines and was observed in vitro as well as in vivo. The 
efficacy of shRNA based FGFR1 knock-down was far more prominent in ES than in 
several other cancer types, such as lung cancer, that had previously been described 
to be associated with FGFR1 activity (42). Ponatinib as a FGFR1 inhibitor (39) 
showed significant activity towards proliferation of ES cell lines in our experiments. Of 
note, proliferation of all ES cell lines was inhibited by Ponatinib (Supp. Fig. 6C). 
 Ewing sarcoma cells appear to be far more addicted to FGFR1 signaling than carci-
noma cells which implies that FGFR1 inhibitors should be tested in ES. In addition to 
the pre-clinical data for Ponatinib, we also treated one patient with ES, who had ex-
hausted all available therapy options, with Ponatinib monotherapy. Tumor activity 
was assessed by positron emission tomography scanning. After 3 weeks of therapy, 
18F-FDG-glucose uptake was widely reduced. This may be due to FGFR1 inhibition, 
but we do not rule out at all that other TKs may be involved. Taken together, these 
data suggest, that FGFR1 might be a suitable therapeutic target in ES. Two main 
conclusions that can be drawn from our data concern the role of tyrosine kinase al-
terations in ES and the approaches to identify driver mutations in cancers with a low 
frequency of recurrent mutations. Mutations, that are not found to be recurrent in a 
significant fraction of cancers, are usually considered to be bystander or passenger 
mutations. In many studies, these mutations are neglected, but the direct association 
between non-recurrent and non-functional, e.g. as passenger mutation, might be mis-
leading. An important role for FGFR1 in ES pathogenesis is evident not only by the 
oncogenic point mutation but also by gene copy gain and knock-down studies. Thus, 
DNA-sequencing alone is obviously not sufficient to assign relevant mutations and 
driver events due to the low frequency of these events in ES. In contrast, the combi-
nation of protein expression, genomics and functional analysis provided evidence for 
the involvement of FGFR1 in ES pathogenesis. Given the high frequency of trisomy 
8, it can be envisioned, that about half of all ES patients show copy number gain of 
FGFR1 on the genetic level. Increased protein expression, that might be even more 
widespread, can also be influenced and induced by multiple other mechanisms, 
many of these obviously need to be defined for future studies. 
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Cancers with balanced translocations provide a unique opportunity to identify coop-
erating events. In some leukemias, a two hit model was proposed that depends on a 
balanced translocation predominantly affecting self-renewal and differentiation (45). 
An increased tyrosine kinase activity is a cooperating event that was thought to be 
responsible preferentially for increased proliferative and anti-apoptotic activity. It is 
obvious that this kind of model is overly simplistic for ES and FGFR1 alterations are 
just one event that cooperates with EWS/ETS translocations.  
In summary, our data provide evidence, that integration of genomic data with gene 
copy number gain, expression and functional analysis are crucial to identify oncogen-
ic drivers in cancers with low rates of recurrent mutations. FGFR1 may constitute a 
novel target for therapeutic approaches in Ewing sarcoma.
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FIGURE LEGENDS 
Figure 1. Combined patient characteristics and subjected methods. For Whole 
Genome (WGS, green) and Whole Exome Sequencing (WES) tumor samples de-
rived from 52 Ewing sarcoma patients were used. A discovery data set of 14 
matched tumor-normal pairs (orange) allowed identification of somatic mutations and 
analysis of chr8 amplification. FGFR1 copy number (CNV) was analyzed by real time 
PCR. Expression of FGFR1 was determined either on RNA level by microarray tech-
nology or real time PCR or on protein level by immunohistochemistry (IHC). Addi-
tional sarcomas were analyzed for FGFR1 expression or CNV only (Supplementary 
Fig. S1)   
 
Figure 2. Whole genome sequencing analysis of Ewing sarcomas. (A) Frequen-
cy of somatic mutations per megabase of genomic DNA in primary and relapsed 
samples. A two to three-fold increase was shown for each relapse.  (B) Classification 
of somatic mutations using a tier-4 scheme (tier 1 = within coding regions, tier 2 = 
within conserved regions, tier 3 = non-repetitive regions, and tier 4 = the remaining 
ones). (C) Percentage of the observed mutations within the six different possible 
base-pair substitutions. (D) Clonality analysis based on mutant allele frequency in 
WGS data. Only SNV for sequenced alleles with > 50x coverage were used. Allele 
frequency was not corrected for DNA contribution of non-tumor cells.  
 
Figure 3. Whole exome sequencing analysis of Ewing sarcoma; analysis of 
somatic mutations in 14 tumor-normal pairs (7 primary, 6 relapsed and for one 
both; male:female 1:1; median age at sampling 18,4 years, range 5-47 y). (A) Fre-
quency of protein-coding (non-syn) and silent somatic mutations (syn) per megabase 
of genomic DNA. (B) Number of observed somatic mutations per age. Each dot rep-
resents an individual patient. (C) Quantity of somatic mutations in newly diagnosed 
patients (primary) and patient samples with relapsed disease. (D) Percentage of the 
observed mutations within the six different possible base-pair substitutions. (E) Ob-
served copy number variations across autosomes in individual tumor-normal pairs of 
the exome discovery data set. 
 
Figure 4. FGFR1 in Ewing sarcomas. (A) Structure, functional domains and known 
and identified (p.N546K) recurrent somatic mutations of FGFR1 (Fig. modified ac-
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cording to NCBI). (B) FGFR1 targeting interphase FISH in cell lines of the Ewing sar-
coma family using a FGFR1 locus specific break apart probe spanning 1.1 Mbp 
(red/green) and a centromere 8 probe (red). (C) FGFR1 copy number in Ewing sar-
coma determined by TaqMan based copy number assays. Duplexed real time PCRs 
targeting human FGFR1 and RNase P were performed to calculate copy number us-
ing Copy Caller 2 software (Life Technologies) (D) Correlation of FGFR1 copy num-
ber and gene expression. Copy number (CN) was determined as explained above 
and RNA expression by means of SYBR green real-time PCR. GAPDH was used as 
housekeeping gene and FGFR1 expression was calculated relative to the expression 
in the ES cell line VH-64 using the 2^-delta CT method. Expression correlated signifi-
cantly with copy number as calculated with the Wilcoxon signed-rank test (CN2, 
n=16; CN3, n=10; CN4, n=1). (E) FGFR1 expression (0=neg, 1=weak, 2=mod., 
3=strong) in Ewing sarcoma by means of immunohistochemistry (IHC). (F) IHC of 
FGFR1 of representative Ewing sarcoma samples (IHC intensities: ES068=0, 
ES074=1, ES026=2, ES080=3). 
 
Figure 5. Functional analyses of FGFR1. (A) Proliferation of NIH-3T3 cells ex-
pressing a control (empty vector), wildtype (WT) or mutant (MUT) FGFR1. (B) Colony 
forming capacity of NIH-3T3 cells according to wildtype and mutant FGFR1 expres-
sion. (C) Representative colonies of NIH-3T3 cells expressing a control (EV), 
wildtype (WT) or mutant (MUT) FGFR1. Only FGFR1 expressing cells (WT and MUT) 
showed three-dimensional clusters indicating cellular transformation. (D) Diagram of 
the generation of A673 FGFR1 knock-down cells by lentiviral transduction and their 
use for in vitro and in vivo analyses. (E) Proliferation of cell lines after lentiviral infec-
tion with scrambled (pLKO_shcontrol) or FGFR1 specific shRNA constructs 
(pLKO_shFGFR1) (Ewing sarcoma family: A673 and SK-NMC; leukemia: HL60 and 
KASUMI, lung carcinoma: A549). (F) Mice were injected with A673 cells infected with 
scrambled shRNA (pLKO_shcontrol) or FGFR1 shRNA (pLKO_shFGFR1). Tumor 
growth until day 50 is shown. (G) Survival curve of Rag2-/-γc-/- mice after s.c. injection 
of A673 FGFR1 shRNA (pLKO_shFGFR1) and scrambled shRNA transduced  
(pLKO_shcontrol) cells, respectively as shown in 5F. Only one mouse of the group of 
mice injected with A673 FGFR1 shRNA infectants (pLKO_shFGFR1) developed a 
tumor at day 67 after inoculation. 
 





Table 1: Genes with significant frequencies of recurrent mutations across 50 Ewing sarcoma. 
name gene description recurrence
frequency 
(%) p-value* q-value*
expression 
(FC)** comment
ANKRD30A ankyrin repeat domain 30A 5 9.6 4.11E-05 1 1.02 ubiquitious
CCDC19 coiled-coil domain containing 19 6 11.5 4.39E-04 1 0.92 ubiquitious
KIAA0319 --- 4 7.7 1.20E-02 1 0.57 increased in fetal brain
KIAA1522 --- 4 7.7 1.60E-02 1 0.69 increased in brain, fetal brain
LAMB4 laminin, beta 4 5 9.6 3.57E-02 1 1.03 ubiquitious
SLFN11 schlafen family member 11 4 7.7 1.60E-02 1 10.91 increase in ES
STAG2 stromal antigen 2  6 11.5 4.74E-05 4.47E-01 2.10 increase in ES, also in cerebellum
TP53 tumor protein p53 3 5.7 4.46E-04 1 1.79 increase in ES
UNC80 unc-80 homolog  4 7.7 4.32E-02 1 0.36 increased in brain
ZNF98 zinc finger protein 98 4 7.7 1.08E-02 1 1.34 ubiquitious
*based on MutSigCV algorithm (http://www.broadinstitute.org/cancer/cga/mutsig) 
**FC: fold change of expression of ES samples compared to a normal body map (GSE45544) 
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Supplemental table:  Characteristics of the discovery data set for exome sequencing 
 
gender 
av. 
coverage 
normal 
av. 
coverage 
tumor 
syn. 
mutations 
damag. 
mutations 
age at 
sample (y) stage ews/fli1 
ES002 male 101.55 112.2 4 17 12 relapse + 
ES003 male 107.87 109.41 6 7 16 relapse + 
ES006 female 108.64 109.62 9 32 18 relapse - 
ES009 male 93.63 82.36 -- -- 15 relapse - 
ES010 male 134.59 129.16 3 10 26 primary NA 
ES011 male 66.33 143.68 -- 5 6 primary - 
ES014 female 104.55 117.16 -- 12 17 primary + 
ES014M female 104.55 
 
-- 19 18 relapse + 
ES016 male 103.21 104.7 11 9 26 primary + 
ES017 female 119.03 95.76 3 9 21 primary + 
ES018 female 139.89 126.65 7 19 47 relapse + 
ES020 female 87.03 118.02 1 -- 5 primary NA 
ES022 female 138.88 135.24 7 5 7 primary + 
ES023 male 151.29 137.6 6 7 26 primary + 
ES024 female 139.4 150.9 7 14 17 relapse + 
 
 
 Supplemental table:  Characteristics of the expression data set  
  Gender age at sample EWS/FLI1 stage localization 
ES002 m 12 positive relapse Os ilium 
ES004 w 18 positive relapse Os sacrum 
ES004cl w 18 positive relapse cell line 
ES005 w 14 positive relapse left proximal fibula 
ES005cl w 14 positive relapse cell line 
ES006 w 18 negative relapse lung metastasis 
ES008a m 15 positive relapse lung metastasis 
ES008a m 15 positive relapse lung metastasis 
ES009 m 15 negative relapse r.prx.humerus 
ES010 m 26 NA primary lung metastasis 
ES011 m 6 negative primary C2-C5 
ES013cl w 19 positive relapse cell line 
ES014 w 17 positive primary 2.+3.rib 
ES015 w 14 positive primary Os ileum 
ES017 w 21 positive primary femur 
ES018 w 47 positive relapse perirenal 
ES019 w 14 positive primary 5.rib 
ES019M w 16 positive  relapse lung metastasis 
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Supplementary Fig S1: Combined patient characteristics and subjected methods. Additional samples were used to determine FGFR1 
copy number and analysis of gene expression by means of real time PCR or immunohistochemistry (IHC) 
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Supplementary Fig. S2 A: ROC curves were constructed by using the somatic 
scores from the sequenced genotypes. We accepted a true positive rate of 0.85 and 
a false positive rate of 0.1 resulting in a somatic score cutoff of -5. B and C: A 2- to 
3-fold increase in mutation rate for each relapse was confirmed for several mutation 
types like deletions, insertions, multiple and single nucleotide variations on the 
genomic level. This holds true for exonic variants showing different effects, too. 
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Supplementary Fig. S3: Circos plots of representative Ewing sarcomas. (A) Circos 
plots displaying the distribution of mutations in primary (outer circles) and relapsed 
(inner circles) samples were derived using the R packages VariantAnnotation and 
ggbio. (B) Circos plot tracks representing verified somatic mutations, from outside 
circle; mutated genes missense mutations (black), nonsense and indel mutations 
(red); genomic location, genome wide copy-number alterations, increased allele 
frequency (green), lesser allele frequency (blue). ES006, late relapsed tumor; ES014, 
primary tumor with TP53 mutation in adolescence, ES014R, early relapse of ES014; 
ES018 relapsed tumor of adulthood, ES022, primary disease in infancy. ES006 has 
no EWS/FLI1 translocation. 
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Supplementary Fig. S4: Sanger sequencing results confirmed (A) somatic 
inactivating mutations of the STAG2 gene (positions according to RefSeq NG 
033796.2) and (B) the activating N546 mutation of FGFR1. 
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Supplementary Fig. S5: FGFR-1 expression in Ewing Sarcomas by means of real 
time RT PCR (A, normalized to FGFR-1 expression in VH-64). (B) Array-based 
analysis of FGFR1 expression in ES compared to normal tissue (NBA; SI Materials 
and Methods). (C) Knock-down by means of lentiviral transduced FGFR1.shRNA 
effectively reduced FGFR1 mRNA expression by 70 % or more in Ewing sarcoma 
cell lines as compared to scrambled shRNA. (D) Knockdown was confirmed on the 
protein level by means of western blotting. 
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Supplementary Fig. S6: Amplification of the FGFR-1 gene (A) as well as gene 
expression (B) are associated with a trend towards inferior survival in patients with 
ES.  (C) Treatment with Ponatinib inhibited growth of ES cell lines significantly. (D) 
FGFR1 tyrosine kinase inhibitor therapy in a patient with relapsed Ewing sarcoma. 
FDG-PET showing physiological bone marrow uptake in the spine of a patient with a 
Ewing sarcoma after multiple lines of therapy on Feb 12th 2013 (a, tumor activity is 
represented by yellow-reddish areas), progressive multifocal spinal metastasis with 
maximum specific uptake value (SUV) of 8.3 on November 28th (b), and rapid 
metabolic response to 3 weeks of pazopanib (c, d) with maximum SUV of 5.3 on 
December 19th, 2013 (d). 
Patient Sample Chr. Position GeneSymbol IGV_quality REF ALT Somatic SomaticScore Verified
PAT1 2relapse chr10 89711876 PTEN 463 G A S 17 1
PAT1 2relapse chr17 66873736 ABCA8 764 T C S 17 1
PAT1 2relapse chrx 144909344 TMEM257 469 T C S 14 1
PAT2 2relapse chr17 30315518 SUZ12 315 T C S 13 1
PAT1 2relapse chr1 979721 AGRN 770 G T S 12 1
PAT1 2relapse chr6 46517749 CYP39A1 438 A G S 8 1
PAT1 2relapse chr8 38274849 FGFR1 417 G C S 8 1
PAT1 1relapse chr6 46517749 CYP39A1 130 A G S 8 1
PAT2 2relapse chr21 41711193 DSCAM 350 G A S 7 1
PAT1 1relapse chr10 73556894 CDH23 250 GA G S 7 0
PAT1 2relapse chr1 160100356 ATP1A2 587 C A S 5 1
PAT2 2relapse chr17 29622330 NF1/OMG 617 CTG C S 5 1
PAT1 1relapse chr11 7723786 OVCH2 522 TGAC T S 5 0
PAT1 2relapse chr11 7723786 OVCH2 1333 TGAC T S 4 1
PAT1 2relapse chr10 73556894 CDH23 1270 GA G S 4 1
PAT1 1relapse chr17 66873736 ABCA8 185 T C S 2 1
PAT2 2relapse chr5 36608664 SLC1A3 477 C T S 1 1
MP primary chr16 9984874 GRIN2A 618 A G S 0 1
PAT1 1relapse chr1 979721 AGRN 130 G T S -2 1
PAT1 2relapse chr7 151877884 MLL3 280 TGGGAGA CACAGGT S -9 0
PAT2 primary chr7 72412651 POM121 354 G GGAACACAGAACACA S -9 0
PAT1 1relapse chr8 38274849 FGFR1 80 G C S -10 1
PAT2 1relapse chr12 53189413 KRT3 56 A ACCAAAGCCACCAGCCCCT S -12 0
PAT1 1relapse chr3 75790879 ZNF717 274 CA TG S -13 1
PAT1 2relapse chr16 1364074 UBE2I 133 G GA S -14 0
MP primary chr12 53189413 KRT3 44 A ACCAAAGCCACCAGCCCCT S -16 0
PAT1 2relapse chr3 127800237 RUVBL1 63 C CA S -20 0
PAT1 1relapse chr11 119170313 CBL 61 C CA S -21 1
PAT1 1relapse chr3 18391053 SATB1 73 GGA CAT S -23 0
PAT1 2relapse chr15 72192157 MYO9A 33 C T S -24 0
PAT1 2relapse chr12 56494996 ERBB3 70 GG AA S -24 0
PAT1 1relapse chr22 29130677 CHEK2 60 CTG GTC S -25 0
PAT1 2relapse chr3 184298793 EPHB3 47 GCCA G S -26 0
PAT1 2relapse chr12 52912923 KRT5 53 T TCTG S -26 0
PAT1 2relapse chr3 18391053 SATB1 53 GGA CAT S -26 0
PAT1 2relapse chr2 10580963 ODC1 50 AGTC TTCG S -28 0
PAT1 2relapse chr15 72192154 MYO9A 33 C CA S -29 0
PAT1 1relapse chr1 226570777 PARP1 21 CT C S -29 0
PAT1 2relapse chr2 41546137 EP300 27 C G S -32 0
PAT1 2relapse chr9 132515246 PTGES 25 A G S -32 0
PAT1 2relapse chr2 11332379 ROCK2 25 TG T S -33 0
PAT1 2relapse chr7 151879605 MLL3 24 C CT S -36 0
PAT1 2relapse chr2 25994332 ASXL2 42 G GT S -37 0
PAT1 2relapse chr1 120465012 NOTCH2 23 A ACAACAGCAACAG S -37 0
PAT1 2relapse chr3 119582341 GSK3B 22 C CA S -39 0
PAT1 2relapse chr6 101076917 ASCC3 23 A T S -39 0
PAT1 2relapse chr3 25661402 Top2B 20 C G S -40 0
Supplementary Table S1 : Validation of somatic mutations by Sanger sequencing for construction of ROC
patient gender
av. coverage 
normal
av. coverage 
tumor
syn. 
mutations
damag. 
mutations
age at sample 
(y)
stage ews/fli1
ES002 male 101.55 112.2 5 17 12 relapse +
ES003 male 107.87 109.41 6 6 16 relapse +
ES006 female 108.64 109.62 9 32 18 relapse -
ES009 male 93.63 82.36 0 0 15 relapse -
ES010 male 134.59 129.16 3 10 26 primary NA
ES011 male 66.33 143.68 1 5 6 primary -
ES014 female 104.55 117.16 0 13 17 primary +
ES014M female 104.55 0 19 18 relapse +
ES016 male 103.21 104.7 11 9 26 primary +
ES017 female 119.03 95.76 3 9 21 primary +
ES018 female 139.89 126.65 7 19 47 relapse +
ES020 female 87.03 118.02 1 1 5 primary NA
ES022 female 138.88 135.24 7 5 7 primary +
ES023 male 151.29 137.6 6 7 26 primary +
ES024 female 139.4 150.9 7 14 17 relapse +
Supplementary Table S2:  Characteristics of the discovery data set for exome sequencing
Patient idsnv Type Genomic position Transcript cDNA level Protein level Genesymbol
3592383 missense chr17:g.36829628A>T NM_001130677.1 c.1121T>A p.(Ile374Asn) C17orf96
3592652 nonsense chr7:g.56126116G>T NM_001762.3 c.787G>T p.(Glu263*) CCT6A
3592686 nonsense chr8:g.27362520G>T NM_001979.5 c.394G>T p.(Glu132*) EPHX2
3592471 frameshift
chr2:g.214012450_ 
214012451dup NM_016260.2 c.120_121dup p.(Pro41Hisfs*5) IKZF2
3592722 missense chr9:g.125582606T>C NM_005388.4 c.664A>G p.(Ile222Val) PDCL
4217685 splice chr10:g.133753533A>G NM_018461.3 c.101-2A>G PPP2R2D
3592544 missense chr3:g.187416543C>T NM_001004312.2 c.421G>A p.(Val141Met) RTP2
4217698 missense chr12:g.21051398G>T NM_019844.3 c.1711G>T p.(Ala571Ser)
SLCO1B7, 
SLCO1B3
3593639 indel
chr11:g.108788636_ 
108788638delTGA NM_004398.2
c.2341_2343d
elTGA p.(Asp788del) DDX10
3594142 splice chr6:g.24580085C>T NM_001168375.1 c.1372+1G>A KIAA0319
3594296 frameshift
chrX:g.123202421_ 
123202422insA NM_006603.4
c.2273_2274i
nsA p.(Leu759Alafs*26) STAG2
3595700 missense chr9:g.131085204G>A NM_016035.3 c.67G>A p.(Ala23Thr) COQ4
3595089 missense chr10:g.25273690G>A NM_001270383.1 c.553C>T p.(His185Tyr) ENKUR
3595384 missense chr2:g.112939358G>A NM_153214.2 c.575G>A p.(Arg192His) FBLN7
3595120 missense chr11:g.43837003G>A NM_016142.2 c.408G>A p.(Met136Ile) HSD17B12
3595150 missense chr11:g.123900744T>C NM_001004464.1 c.415T>C p.(Ser139Pro) OR10G8
3595716 missense chrX:g.48690553C>T NM_013271.2 c.313G>A p.(Val105Ile) PCSK1N
3595425 missense chr20:g.44053216G>A NM_001184728.2 c.1313G>A p.(Ser438Asn) PIGT
3595421 missense chr20:g.32307938C>A NM_007238.4 c.76G>T p.(Ala26Ser) PXMP4
3595042 missense chr1:g.87194116A>G NM_001206651.1 c.601A>G p.(Asn201Asp) SH3GLB1
3595500 missense chr3:g.100455534C>A NM_001007565.2 c.695C>A p.(Ala232Asp) TFG
3595034 nonsense chr1:g.36758258A>T NM_005119.3 c.1978A>T p.(Arg660*) THRAP3
3595209 splice chr14:g.71134464G>A NM_015351.1 c.589+1G>A TTC9
3595575 splice chr5:g.123979936C>G NM_020747.2 c.4123+1G>C ZNF608
4280089 missense chr19:g.54496234C>T NM_031897.2 c.103C>T p.(Arg35Cys) CACNG6
4281021 nonsense chrX:g.123220440C>T NM_006603.4 c.3097C>T p.(Arg1033*) STAG2
4279658 missense chr14:g.51713856A>G NM_030755.4 c.361A>G p.(Lys121Glu) TMX1
4836684 missense chr14:g.96924502C>T NM_152327.3 c.1310C>T p.(Ala437Val) AK7
4836706 nonsense chr15:g.69331323C>T NM_024505.2 c.1444C>T p.(Gln482*) NOX5
5622078 missense chr20:g.44054365C>A NM_001184728.2 c.1468C>A p.(Leu490Ile) PIGT
5622235 frameshift
chr7:g.108113090_ 
108113093delGTAA NM_015723.3
c.2101_2104d
elTTAC p.(Pro702Leufs*10) PNPLA8
4837091 missense chr6:g.110746218C>A NM_033125.3 c.1592G>T p.(Arg531Leu) SLC22A16
5621703 missense chr1:g.43919337T>A NM_001190880.2 c.128A>T p.(Glu43Val) SZT2, HYI
4836773 nonsense chr17:g.7577022G>A NM_000546.5 c.916C>T p.(Arg306*) TP53
4836866 missense chr19:g.44377564C>A NM_001033719.2 c.802G>T p.(Val268Leu) ZNF404
4836684 missense chr14:g.96924502C>T NM_152327.3 c.1310C>T p.(Ala437Val) AK7
4836706 nonsense chr15:g.69331323C>T NM_001184779.1 c.1414C>T p.(Gln472*) NOX5
4837091 missense chr6:g.110746218C>T NM_033125.3 c.1592G>A p.(Arg531Gln) SLC22A16
4836773 nonsense chr17:g.7577022G>A NM_000546.5 c.916C>T p.(Arg306*) TP53
4836866 missense chr19:g.44377564C>A NM_001033719.2 c.802G>T p.(Val268Leu) ZNF404
5270500 missense chr17:g.28890301G>A NM_015594.2 c.311G>A p.(Ser104Asn) TBC1D29
5930327 nonsense chr19:g.22585629C>T NM_001098626.1 c.215G>A p.(Trp72*) ZNF98
5425106 missense chr1:g.32667679A>G NM_024296.3 c.143A>G p.(Lys48Arg) CCDC28B
5425750 missense chr19:g.42754616A>G NM_006494.2 c.124T>C p.(Tyr42His) ERF
5425751 missense chr19:g.42754617C>G NM_006494.2 c.123G>C p.(Glu41Asp) ERF
5425752 nonsense chr19:g.42754619C>A NM_006494.2 c.121G>T p.(Glu41*) ERF
5201972 missense chrX:g.50653941C>A NM_005448.2 c.158C>A p.(Pro53His) BMP15
5201388 missense chr1:g.209956589G>T NM_152485.2 c.391C>A p.(Gln131Lys) C1orf74
5201648 missense chr19:g.12791093G>A NM_001930.3 c.254C>T p.(Ala85Val) DHPS
5201968 nonsense chrX:g.9864685C>T NM_001649.2 c.2737C>T p.(Gln913*) SHROOM2
2765328 nonsense chr21:g.32575244C>A NM_003253.2 c.2473G>T p.(Glu825*) TIAM1
1616295 missense chr1:g.37346378C>T NM_000831.3 c.407G>A p.(Arg136His) GRIK3
ES017
ES018
Supplementary Table S3: Somatic mutations in the discovery data set (filtered with MutSigCV1.6)
ES016
ES002
ES003
ES006
ES010
ES014
5203738 missense chr1:g.37324743C>T NM_000831.3 c.1070G>A p.(Arg357His) GRIK3
5203888 missense chr4:g.2065657G>A NM_178557.3 c.712G>A p.(Val238Met) NAT8L
5203838 missense chr19:g.22574381G>C NM_001098626.1 c.1656C>G p.(Asn552Lys) ZNF98
5204446 missense chr6:g.42906390C>G NM_006586.3 c.698C>G p.(Ala233Gly) CNPY3
5204402 missense chr4:g.155749035G>A NM_144979.3 c.1418G>A p.(Arg473His) RBM46
5204530 frameshift chrX:g.123191734delC NM_006603.4 c.1325delC p.(Pro442Glnfs*6) STAG2
5204262 nonsense chr19:g.38160389C>A NM_152605.3 c.661G>T p.(Glu221*) ZNF781
5207257 missense chr7:g.102715757G>A NM_001161009.2 c.38G>A p.(Gly13Asp) ARMC10
5207274 frameshift
chrX:g.102004247_ 
102004248insG NM_030639.2
c.324_325ins
G p.(Ala109Glyfs*23) BHLHB9
5207212 nonsense chr20:g.3175969G>A NM_023935.1 c.541C>T p.(Gln181*) DDRGK1
5207213 frameshift chr20:g.21492590delG NM_002509.3 c.793delC p.(Leu265Trpfs*52) NKX2-2
5207275 missense chrX:g.154456697T>C NM_003372.5 c.317T>C p.(Leu106Ser) VBP1
5207177 missense chr17:g.44952541G>A NM_003396.1 c.409G>A p.(Ala137Thr) WNT9B
ES022
ES023
ES024
Supplementary Table S4: Recurent non-synonymous mutations (filtered with MutSigCV1.6)
exome genesymbol type genomic level transcript cDNA level protein level
LAMB4 missense chr7:g.107748092G>C NM_007356.2 c.575C>G p.Pro192Arg
SORT1 missense chr1:g.109940397G>A NM_002959.5 c.118C>T p.Pro40Ser
CLOCK missense chr4:g.56314977G>T NM_004898.3 c.1508C>A p.Thr503Lys
IKZF2 frameshift
chr2:g.214012451_ 
214012452insGA NM_016260.2 c.118_119dup p.Pro41Hisfs*5
SLFN11 missense chr17:g.33689842G>A NM_152270.3 c.985C>T p.Pro329Ser
KIAA0319 splice chr6:g.24580085C>T NM_014809.3 c.1372+1G>A
KIAA1522 missense chr1:g.33237419C>T NM_020888.2 c.2639C>T p.Thr880Met
STAG2 frameshift
chrX:g.123202421_ 
123202422insA NM_006603.4
c.2273_2274ins
A p.Leu759Alafs*26
ZNF28 missense chr19:g.53303257T>A NM_006969.3 c.1841A>T p.Lys614Met
BOLA2 indel
chr16:g.30016629_ 
30016630insCCC NM_173618.1 c.605_607dup p.Pro202dup
PCDHGA10 missense chr5:g.140793410A>G NM_018913.2 c.668A>G p.Asp223Gly
TP53 missense chr17:g.7578406C>T NM_000546.5 c.524G>A p.Arg175His
ERF missense chr19:g.42753077A>G NM_006494.2 c.1187T>C p.Val396Ala
LAMB4 missense chr7:g.107748092G>C NM_007356.2 c.575C>G p.Pro192Arg
PCDHGA5 missense chr5:g.140744449C>G NM_018918.2 c.552C>G p.Ser184Arg
PCDHGB6 missense chr5:g.140788536C>G NM_018926.2 c.767C>G p.Pro256Arg
GABRE missense chrX:g.151138163C>A NM_004961.3 c.320G>T p.Gly107Val
TFG missense chr3:g.100455534C>A NM_006070.5 c.695C>A p.Ala232Asp
TTC9 splice chr14:g.71134464G>A NM_015351.1 c.589+1G>A
ES007 KIAA0319 missense chr6:g.24596361C>T NM_014809.3 c.541G>A p.Glu181Lys
CASP1 missense chr11:g.104897049G>A NM_001223.4 c.1088C>T p.Ala363Val
CCDC19 missense chr1:g.159847226C>A NM_012337.2 c.1071G>T p.Glu357Asp
GABRE missense chrX:g.151138751C>G NM_004961.3 c.180G>C p.Glu60Asp
PSPH missense chr7:g.56155446C>T NM_006213.4 c.107G>A p.Arg36Gln
ES010 STAG2 nonsense chrX:g.123220440C>T NM_006603.4 c.3097C>T p.Arg1033*
ES011 ANKRD30A missense chr10:g.37430778A>T NM_052997.2 c.785A>T p.Glu262Val
LAMB4 frameshift
chr7:g.107738853_107738
854 
insAGCCCATAGGGGTTG
ATGGACACTCCCCCGAC
CCCCGACTATGGACTTA
CGCTGGC
NM_007356.2
c.1354_1355ins
GCCAGCGTAA
GTCCATAGTC
GGGGGTCGG
GGGAGTGTCC
ATCAACCCCT
ATGGGCT
p.Pro454Argfs*32
SLFN11 indel
chr17:g.33681035_ 
33681037delCCT NM_152270.3
c.1240_1242del
AGG p.Arg414del
TP53 missense chr17:g.7577121G>A NM_000546.5 c.817C>T p.Arg273Cys
AK7 missense chr14:g.96924502C>T NM_152327.3 c.1310C>T p.Ala437Val
NOX5 nonsense chr15:g.69331323C>T NM_024505.3 c.1498C>T p.Gln500*
TP53 nonsense chr17:g.7577022G>A NM_000546.5 c.916C>T p.Arg306*
ES015 KIAA1522 missense chr1:g.33233394C>T NM_020888.2 c.242C>T p.Ala81Val
CCDC19 missense chr1:g.159854353C>T NM_012337.2 c.770G>A p.Gly257Glu
ZNF98 nonsense chr19:g.22585629C>T NM_001098626.1 c.215G>A p.Trp72*
ERF missense
chr19:g.42754616_ 
42754617delACinsGG NM_006494.2
c.123_124delins
CC p.Glu41_Tyr42delinsAspHis
ERF nonsense chr19:g.42754619C>A NM_006494.2 c.121G>T p.Glu41*
ES017 LAMB4 missense chr7:g.107749644C>T NM_007356.2 c.374G>A p.Arg125Gln
C1orf74 missense chr1:g.209956589G>T NM_152485.2 c.391C>A p.Gln131Lys
CASP1 missense chr11:g.104904946C>T NM_001223.4 c.263G>A p.Gly88Glu
ES021 SORT1 missense chr1:g.109870193T>C NM_002959.5 c.1402A>G p.Ile468Val
ES022 ZNF98 missense chr19:g.22574381G>C NM_001098626.1 c.1656C>G p.Asn552Lys
STAG2 frameshift
chrX:g.123191735_ 
123191735delC NM_006603.4 c.1324delC p.Pro442Glnfs*6
ZNF781 nonsense chr19:g.38160389C>A NM_152605.3 c.661G>T p.Glu221*
DDRGK1 nonsense chr20:g.3175969G>A NM_023935.1 c.541C>T p.Gln181*
NKX2-2 frameshift
chr20:g.21492590_ 
21492590delG NM_002509.3 c.793delC p.Leu265Trpfs*52
ES018
ES023
ES024
ES017
ES001
ES002
ES003
ES004
ES005
ES006
ES008
ES013
ES014
ES016
UNC80 missense chr2:g.210698793G>T NM_032504.1 c.2843G>T p.Arg948Ile
ADAM8 missense chr10:g.135087305G>A NM_001109.4 c.344C>T p.Pro115Leu
CCDC19 nonsense chr1:g.159847249G>A NM_012337.2 c.1048C>T p.Arg350*
NOX5 missense chr15:g.69347820G>T NM_024505.3 c.2146G>T p.Gly716Trp
ZNF98 missense chr19:g.22575381T>C NM_001098626.1 c.656A>G p.Tyr219Cys
CLOCK missense chr4:g.56315645G>A NM_004898.3 c.1367C>T p.Pro456Leu
STAG2 missense chrX:g.123197863G>A NM_006603.4 c.1987G>A p.Asp663Asn
ANKRD30A missense chr10:g.37454055A>G NM_052997.2 c.1868A>G p.Asp623Gly
KIAA1522 missense chr1:g.33234352C>T NM_020888.2 c.562C>T p.Arg188Cys
PCDHGB3 missense chr5:g.140750710A>G NM_018924.2 c.749A>G p.Asn250Ser
AK7 indel
chr14:g.96864455_ 
96864456insAGAGGA NM_152327.3 c.165_170dup p.Glu55_Glu56dup
DDRGK1 missense chr20:g.3183933A>G NM_023935.1 c.221T>C p.Leu74Pro
SLFN11 missense chr17:g.33680103C>G NM_152270.3 c.1978G>C p.Glu660Gln
TFG missense chr3:g.100432537G>A NM_006070.5 c.8G>A p.Gly3Glu
UNC80 nonsense chr2:g.210704130C>T NM_032504.1 c.3226C>T p.Arg1076*
PCDHGA4 nonsense chr5:g.140736337C>T NM_018917.2 c.1570C>T p.Gln524*
PSPH missense chr7:g.56155359C>T NM_006213.4 c.194G>A p.Arg65Gln
ANKRD30A missense chr10:g.37454055A>G NM_052997.2 c.1868A>G p.Asp623Gly
KIAA1522 missense chr1:g.33234352C>T NM_020888.2 c.562C>T p.Arg188Cys
PCDHGB3 missense chr5:g.140750710A>G NM_018924.2 c.749A>G p.Asn250Ser
ES036 CTNNAL1 missense chr9:g.111735059G>T NM_003798.2 c.1243C>A p.His415Asn
ANKRD30A nonsense chr10:g.37414929C>T NM_052997.2 c.46C>T p.Gln16*
IKZF2 missense chr2:g.213921679T>C NM_016260.2 c.284A>G p.Lys95Arg
ES038 SLFN11 missense chr17:g.33680404G>A NM_152270.3 c.1873C>T p.His625Tyr
ANKRD30A missense chr10:g.37508799T>G NM_052997.2 c.3991T>G p.Tyr1331Asp
CLOCK missense chr4:g.56304679T>C NM_004898.3 c.2131A>G p.Thr711Ala
KIAA0319 missense chr6:g.24583877T>A NM_014809.3 c.1048A>T p.Asn350Tyr
KIAA1522 missense chr1:g.33235673G>A NM_020888.2 c.893G>A p.Arg298His
UNC80 missense chr2:g.210658510T>C NM_032504.1 c.865T>C p.Cys289Arg
ES043 PCDHGA10 missense chr5:g.140794730C>T NM_018913.2 c.1988C>T p.Thr663Met
ES044 AK7 missense chr14:g.96871109G>T NM_152327.3 c.310G>T p.Asp104Tyr
ES045 STAG2 missense chrX:g.123229296A>T NM_006603.4 c.3669A>T p.Glu1223Asp
ADAM8 missense chr10:g.135087474G>A NM_001109.4 c.287C>T p.Thr96Met
CCDC19 missense chr1:g.159863011C>T NM_012337.2 c.88G>A p.Val30Met
GABRE missense chrX:g.151128397T>A NM_004961.3 c.698A>T p.Glu233Val
PCDHGA4 missense chr5:g.140735207A>C NM_018917.2 c.440A>C p.Asn147Thr
ADAM8 missense chr10:g.135085434C>T NM_001109.4 c.982G>A p.Val328Met
PCDHGA4 missense chr5:g.140735405C>A NM_018917.2 c.638C>A p.Thr213Lys
STAG2 splice chrX:g.123211910T>C NM_006603.4 c.2775+2T>C
ZNF781 missense chr19:g.38160854A>G NM_152605.3 c.196T>C p.Cys66Arg
CCDC19 missense chr1:g.159850436T>C NM_012337.2 c.952A>G p.Ile318Val
CCDC19 indel
chr1:g.159857737_159857
748delTTCTTGTTGTTG NM_012337.2
c.471_482delC
AACAACAAGA
A
p.Asn157_Lys160del
CCDC19 missense chr1:g.159858193T>G NM_012337.2 c.366A>C p.Glu122Asp
KIAA0319 missense chr6:g.24596112A>T NM_014809.3 c.790T>A p.Ser264Thr
ZNF28 frameshift
chr19:g.53304469_ 
53304470delAT NM_006969.3 c.628_629delAT p.Met210Glufs*9
ES049 C1orf74 missense chr1:g.209956756C>G NM_152485.2 c.224G>C p.Gly75Ala
ES050 ZNF98 missense chr19:g.22585674G>A NM_001098626.1 c.170C>T p.Ser57Phe
CTNNAL1 indel
chr9:g.111745547_ 
111745549delCTT NM_003798.2
c.776_778delAA
G p.Glu259del
LAMB4 stoploss chr7:g.107664484C>G NM_007356.2 c.5286G>C p.*1762Tyrext*24
PCDHGA5 missense chr5:g.140746041G>T NM_018918.2 c.2144G>T p.Arg715Ile
CASP1 missense chr11:g.104905028C>T NM_001223.4 c.181G>A p.Val61Ile
UNC80 missense chr2:g.210707144A>C NM_032504.1 c.3434A>C p.Glu1145Ala
ES052
ES040
ES041
ES046
ES047
ES048
ES051
ES037
ES025
ES026
ES027
ES029
ES030
ES032
ES034
ES035
Gender
age at 
sample
EWS/FLI1 stage localization
ES002 m 12 positive relapse Os ilium
ES004 w 18 positive relapse Os sacrum
ES004cl w 18 positive relapse cell line
ES005 w 14 positive relapse left proximal fibula
ES005cl w 14 positive relapse cell line
ES006 w 18 negative relapse lung metastasis
ES008a m 15 positive relapse lung metastasis
ES008a m 15 positive relapse lung metastasis
ES009 m 15 negative relapse r.prx.humerus
ES010 m 26 NA primary lung metastasis
ES011 m 6 negative primary C2-C5
ES013cl w 19 positive relapse cell line
ES014 w 17 positive primary 2.+3.rib
ES015 w 14 positive primary Os ileum
ES017 w 21 positive primary femur
ES018 w 47 positive relapse perirenal
ES019 w 14 positive primary 5.rib
ES019M w 16 positive  relapse lung metastasis
Supplementary Table S5:  Characteristics of the expression data set
chr position Ref Alt gene ID chr position Ref Alt gene ID
1 979721 G T PERM1 2 64069694 C T AC012368.6
1 6215659 C T RNF207 4 12641941 G A AC093809.3
1 160100356 C A AL121987.34 11 128486291 G A ETS1
2 208993016 GCAGGTATTGC G AC069205.6 12 119631570 C T TMEM233
3 48623662 A G AC121252.4 19 7677264 C T MCEMP1
3 78140811 C T AC125621.6 19 56549478 G T ZFP28
3 124724191 AACT A KALRN
4 145793890 G T ZNF827
4 188924770 C A AC017063.8 chr position Ref Alt gene ID
5 54422237 G A AC092366.3 8 52232531 T A ST18
5 140501785 G A ANKHD1 14 74454702 A AT AC005479.2
7 4959951 G A AC092032.5
7 100210584 T C STAG3; GATS
8 115296711 G A AC068399.9 chr position Ref Alt gene ID
8 144877468 C A ZNF250 1 65614181 C T LEPR
10 73556893 GA G USP54 11 16010560 T C SOX6
11 7723785 TGAC T AC021427.10 14 24608277 C T GZMH
11 35327776 G A SLC1A2 20 17417408 C A PCSK2
11 55735447 T C AP006437.2
11 55927276 A G AP003033.2
11 63884881 C A MARK2
12 49959406 C A LOC101927318
12 53691839 A G AC073594.31
14 59107477 T G AL359219.4
14 74641352 C G AC007956.5
14 88945439 G A AL133238.3
15 45442842 C T C15orf48 chr position Ref Alt gene ID
15 74907913 C T AC125435.8 14 96924502 C T AK7
16 71683610 G C PHLPP2 12 56639206 C T ANKRD52
17 4726036 G T AC091153.10 15 69331323 C T MIR548H4 NOX5
17 18027808 CCG C ATPAF2 19 69331323 G T MUC16
17 66873736 T C CACNG5 18 77170630 C T NFATC1
17 71434142 C T AC005279.1 8 10466909 G A RP1L1
17 72926890 T C SLC39A11 6 110746218 C T SLC22A16
18 9792163 G T RAB31 17 7577022 G A TP53
18 34646947 A G DTNA 19 44377564 C A ZNF404
19 7830500 CA C EVI5L
19 12460645 C T AC008758.7
19 23544356 T G ZNF675
20 37182626 T C RPN2
20 48127616 G A AL136102.10
22 20137249 C T ZDHHC8
1. relapse n=61; 2. relapse n=109 primary n=27; 1. relapse n=62; 2. relapse 
Supplementary Table S6 : Shared mutations in consecutive sarcomas
 Pat.1  Pat.2
tier 1 mutations: tier 1 mutations: 
primary n=13; 1. relapse n=19
shared between primary and first relapse (n=9)
shared between first and second relapse (n=42) shared between all specimens (n=6)
shared between primary and first relapse only (n=2)
shared between first and second relapse only (n=4)
ES014
tier 1 mutations: 
1 
SUPPORTING INFORMATION 
SI MATERIALS AND METHODS 
Whole genome sequencing 
Somatic single nucleotide variations cutoff 
To obtain high quality somatic variations between matched normal and cancer 
genomes we determined a somatic score cutoff based on the somatic scores 
provided by Complete Genomics, Inc. (40). Out of all cancer genome samples, we 
selected 47 somatic variations at random. According to (41), ROC curves were 
constructed by using the somatic scores from the sequenced genotypes. We 
accepted a true positive rate of 0.85 and a false positive rate of 0.1 resulting in a 
somatic score cutoff of -5. 
Somatic single nucleotide variation rates and annotation 
The somatic variations were annotated and their effects predicted by SnpEff (42). We 
further categorized the somatic mutations by their tiers according to (43). Briefly, tier 
1 includes all somatic mutations located within coding regions, tier 2 holds somatic 
mutations within conserved regions, tier 3 contains variations of non-repetitive 
regions, and tier 4 the remaining ones. The distribution of somatic variations along 
the genome was visualized by circos plots using the R packages VariantAnnotation 
(44)  and ggbio (45). 
Clonality analysis 
To determine the number of different subclones present in the primary and relapsed 
tumor samples, we computed kernel density estimates of the variant allele 
frequencies of somatic single nucleotide variations and assessed their peak regions 
(32, 46). We considered copy number neutral somatic single nucleotide variations 
(2N) with a coverage ≥ 50.  
Exome sequencing 
Mutation Significance 
Significance of discovered mutations in DNA sequencing was analyzed with help of 
the MutSig algorithm (http://www.broadinstitute.org/cancer/cga/mutsig; Version 
MutSigCV1.6), to identify genes that were mutated more often than expected by 
chance given background mutation processes. 
  
2 
Circos Plots 
Circos plots were generated for selected samples by use of the Circos plotting 
software of Complete Genomics (http://www.completegenomics.com/analysis-
tools/cgatools). 
RNA Microarray analysis 
Biotinylated target cRNA was prepared as previously described (3). A detailed 
protocol is available at www.affymetrix.com. Samples were hybridized to Affymetrix 
Human Gene 1.0 ST microarrays and analyzed by Affymetrix software expression 
console, version 1.1. For the data analysis, robust multichip average (RMA) 
normalization was performed, including background correlation, quantile 
normalization, and median polish summary method. Probes of the normal body map 
(NBA) included tissues of normal PBMC, bone marrow, spleen, thymus, stomach (2), 
small intestine, colon w/ mucosa, heart, liver, lung, skeletal muscle, brain (whole), 
brain cerebellum, spinal cord, trachea, salivary gland, prostate, testis, uterus, fetal 
brain, and fetal liver. Array data were submitted at GEO (GSE45544).  
18F-fluorodeoxyglucose positron emission tomography (FDG PET) was 
performed using a PET-CT scanner (mCT, Siemens Molecular Imaging, Hoffman 
Estates, IL). After overnight fasting the patient was injected an average of 227 MBq 
FDG and whole body scans were acquired after 1 hour using contrast enhanced CT 
for attenuation correction, morphological diagnosis and anatomical orientation. 
Scanning and reconstruction parameters were in accordance with the manufacturers 
recommendations. Regional FDG uptake was quantitatively assessed as maximum 
standardized uptake value (SUVmax = maximum concentration of activity in the 
tissue region of interest (kBq/mL) divided by injected activity (MBq/body weight)). 
CLINICAL RESULTS 
A 29-year old female patient was diagnosed with EWS-FLI1 positive Ewing sarcoma 
in July 2009 in Russia. A large tumor of the os ilium was first treated with 8 cycles of 
chemotherapy containing etoposide, ifosfamide, vincristine and doxorubicin followed 
by radiotherapy and further 3 cycles of etoposide, ifosfamide, vincristine and 3 cycles 
of ifosfamide, vincristine and doxorubicin. A first relapse occurred in August 2010 
with metastasis in the lung and multiple skeletal lesions. Six cycles containing 
etoposide, ifosfamide and carboplatin followed by radiotherapy of pelvic and spine 
lesions did not result in a good remission and spread of disease with lesions in pelvic 
3 
bones, femur, scapula, and spine was observed until March 2012. In this situation the 
patient was referred to our center and a new staging revealed the bone lesions 
described and progressive multiple lung metastases. Bone lesions again revealed 
Ewing sarcoma in histology. We have treated the patient with 4 cycles topotecan and 
cyclophosphamide inducing a partial remission followed by 2 cycles of high-dose 
treosulfan and melphalan with autologous stem cell rescue until February 2013. This 
consolidated a good partial remission as shown also in FDG PET (see Figure 6, 
panel A). However, already in July 2013 progressive metastasis in multiple bone 
lesions including the spine and orbita lesions occurred and further 2 cycles of 
irinotecan and temozolomide remained without beneficial effect. Disease progressed 
(see figure 6, panel B) and additional central nervous system including cranial nerves 
metastasis occurred. Meantime, the patient´s tumor was shown to overexpress 
FGFR1. According to the wish of the patient and her family, and upon written 
informed consent we started compassionate use therapy with daily 45 mg oral 
ponatinib (Ariad Pharmaceuticals) as a pan-FGFR inhibitor (1) on November 30, 
2013. At this time rapid clinical progress of the end-stage disease was obvious. 
Within the next 3 weeks the clinical disease progression was stabilized and FDG 
PET showed metabolic response with max. SUV of 8.3 decreasing to 5.3 (see figure 
6, C and D). However, this was not stable and the patient eventually died with clinical 
progress of the CNS metastasis (brain and meninges). 
Data Access: Array data are submitted at GEO (GSE45544). Submission of other 
data has already been started and will be finished soon. 
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